1.325
price up icon0.38%   0.005
after-market Handel nachbörslich: 1.33 0.005 +0.38%
loading
Schlusskurs vom Vortag:
$1.32
Offen:
$1.28
24-Stunden-Volumen:
296.92K
Relative Volume:
0.99
Marktkapitalisierung:
$83.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.08M
KGV:
-1.8151
EPS:
-0.73
Netto-Cashflow:
$-33.68M
1W Leistung:
+8.61%
1M Leistung:
-18.21%
6M Leistung:
-50.19%
1J Leistung:
-64.48%
1-Tages-Spanne:
Value
$1.2275
$1.48
1-Wochen-Bereich:
Value
$1.12
$1.48
52-Wochen-Spanne:
Value
$0.726
$4.2684

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
Firmenname
Galectin Therapeutics Inc
Name
Telefon
678-620-3186
Name
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
Mitarbeiter
14
Name
Twitter
@galectingalt
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
GALT's Discussions on Twitter

Vergleichen Sie GALT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GALT
Galectin Therapeutics Inc
1.325 83.16M 0 -45.08M -33.68M -0.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-08-13 Bestätigt H.C. Wainwright Buy
2019-02-13 Eingeleitet B. Riley FBR Buy
2017-12-07 Bestätigt H.C. Wainwright Buy
2017-11-28 Bestätigt H.C. Wainwright Buy
2017-10-19 Eingeleitet ROTH Capital Buy
2017-03-30 Hochstufung H.C. Wainwright Neutral → Buy
2016-10-03 Herabstufung FBR & Co. Outperform → Mkt Perform
2016-09-29 Herabstufung H.C. Wainwright Buy → Neutral
2016-09-28 Herabstufung ROTH Capital Buy → Sell
2016-03-28 Fortgesetzt H.C. Wainwright Buy
2015-09-21 Eingeleitet H.C. Wainwright Buy
2014-08-01 Herabstufung Aegis Capital Buy → Hold
2014-07-30 Bestätigt MLV & Co Buy
2014-07-29 Bestätigt MLV & Co Buy
2014-04-02 Bestätigt MLV & Co Buy
2014-02-10 Bestätigt Aegis Capital Buy
2014-01-09 Bestätigt Aegis Capital Buy
2013-12-03 Eingeleitet MLV & Co Buy
2013-08-19 Bestätigt Aegis Capital Buy
Alle ansehen

Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten

pulisher
09:40 AM

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

09:40 AM
pulisher
01:36 AM

Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter

01:36 AM
pulisher
01:34 AM

HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World

01:34 AM
pulisher
Apr 06, 2025

FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat

Apr 06, 2025
pulisher
Apr 06, 2025

HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Apr 06, 2025
pulisher
Apr 05, 2025

Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World

Apr 04, 2025
pulisher
Apr 01, 2025

Galectin Therapeutics Reports Promising 2024 Results - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics (GALT) Projected to Post Earnings on Friday - MarketBeat

Mar 31, 2025
pulisher
Mar 28, 2025

PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 21, 2025

Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com

Mar 21, 2025
pulisher
Mar 14, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail

Mar 14, 2025
pulisher
Mar 08, 2025

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance

Mar 08, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks

Mar 05, 2025
pulisher
Feb 26, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor - MSN

Feb 26, 2025
pulisher
Feb 20, 2025

Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World

Feb 20, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World

Feb 15, 2025
pulisher
Feb 04, 2025

Largest borrow rate increases among liquid names - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Feb 04, 2025
pulisher
Jan 30, 2025

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve

Jan 30, 2025
pulisher
Jan 29, 2025

Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR

Jan 29, 2025
pulisher
Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Galectin drops as trial for lead asset fails in MASH - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 25, 2025

Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 21, 2025

HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN

Jan 21, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

SouthState Corporation Announces Sale Agreement with Blue Owl Real Estate Capital On January 8, 2025, SouthState Bank, N.A., a subsidiary of SouthState Corporation, has entered into a significant agreement for the purchase and sale of real property w - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire

Jan 15, 2025
pulisher
Jan 11, 2025

Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World

Jan 11, 2025

Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Kapitalisierung:     |  Volumen (24h):